story of the week
Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
N. Engl. J. Med 2020 May 14;382(20)1894-1905, RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, P Merle, AO Kaseb, D Li, W Verret, DZ Xu, S Hernandez, J Liu, C Huang, S Mulla, Y Wang, HY Lim, AX Zhu, AL ChengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.